Read Larry Connors' blog – Short Term Trading Strategies
In a release, the group noted event details:
Watkins and Zook will join noted bioscience investor and CEO Randal J. Kirk as featured plenary speakers at the conference which draws more than 800 top bioscience leaders and investors, including more than 250 companies and 80 corporate and private investors, representing 30 states and 10 foreign countries.
During his plenary keynote address, Watkins will share real-world and real-time experiences of taking a biotech company from the stage of discovery to that of sustainable growth. As a leader in the biotechnology and pharmaceutical fields, Watkins and his team at HGS, recently garnered global headlines announcing positive results from a Phase 3 trial of the new lupus drug, Benlysta. This milestone represents the first potential breakthrough in lupus treatment in the last 50 years.
Tony Zook will join the plenary "Healthcare Policy Panel" to share his views on how bioscience companies and the federal government can effectively partner to improve the quality of healthcare. In response to the pandemic swine flu outbreak, AstraZeneca's North America CEO and MedImmune's President Zook is a key industry participant in a collaboration with U.S. Department of Health and Human Services (HHS) and public health authorities to provide 42 million flu vaccine doses in the U.S., according to several news reports.
The 2009 Mid-Atlantic Bio Conference's "Healthcare Policy Panel" will bring together health policy leaders from the federal government, who will share the latest policy and regulatory changes, and industry leaders, who will then discuss the potential impact of these steps. In addition to CEO Tony Zook, participants currently confirmed include Senator Ben Cardin (D-Md.) and Representative Anna Eshoo, (D-Calif.).
Highlighted at the invitation only CEO & Investor Dinner, Representative Bob Goodlatte (R-Va.) will speak at the event held on Capitol Hill on Thursday, November 5. Additional prominent scientific, government, and business leaders are expected to address the conference.
Included in the new programming line-up at this year's conference are panel sessions that will tackle two of today's most prevalent issues, H1N1 and biofuels: "Vaccines: Biotech's Next 'Big Thing'" will reveal innovations occurring in vaccine development technology, and "Biofuels--Innovative Biotechnology Meets Commercial Needs" will focus on the latest advancements and emerging technologies arising from the current biofuel boom.
((Comments on this story may be sent to health@closeupmedia.com))
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
